Could a medication exist that blocks the autoimmune attack that causes type 1 diabetes (T1D)? Study doctors are hoping to answer this question in the GleeT1D clinical trial.

Learn More

We want to help!

Beta cells maintain healthy blood sugars. Study doctors are investigating if Gleevec may enable people recently diagnosed with T1D to keep some of their own beta cells.

Learn More

Take the first step

GleeT1D is a clinical research study evaluating a therapy called Gleevec in people recently diagnosed with T1D.

Am I eligible?

GleeT1D is a nationwide effort to study the effect of Gleevec on people newly diagnosed with type 1 diabetes. This study will help medical researchers determine if a short-term course of medication can have a long-term effect on the body’s ability to preserve and make insulin-producing beta cells.

Am I Eligible?

The study has completed enrollment at this time.

Learn more about the research study.

About GleeT1D


Having remaining beta cells means better blood sugar control. We are studying Gleevec to determine if it may prolong the body’s natural insulin production by maintaining healthy beta cells.

What is Gleevec?